{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:15:18Z","timestamp":1760346918126,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ando.2020.04.009","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:17:26Z","timestamp":1588159046000},"page":"163-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Amiodarone-induced thyrotoxicosis"],"prefix":"10.1016","volume":"82","author":[{"given":"Louis","family":"Schubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9opoldine","family":"Bricaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Groussin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ando.2020.04.009_bib0160","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid: official journal of the American Thyroid Association"},{"issue":"2","key":"10.1016\/j.ando.2020.04.009_bib0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"European Thyroid Journal"},{"issue":"5","key":"10.1016\/j.ando.2020.04.009_bib0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tcm.2018.09.005","article-title":"Amiodarone and thyroid physiology, pathophysiology, diagnosis and management","volume":"29","author":"Trohman","year":"2019","journal-title":"Trends in cardiovascular medicine"},{"issue":"8","key":"10.1016\/j.ando.2020.04.009_bib0175","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJMra1901214","article-title":"Drug Effects on the Thyroid","volume":"381","author":"Burch","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.ando.2020.04.009_bib0180","doi-asserted-by":"crossref","DOI":"10.1177\/2333392819844635","article-title":"Adherence to Monitoring Guidelines of Amiodarone Adverse Reactions","volume":"6","author":"Lavon","year":"2019","journal-title":"Health services research and managerial epidemiology"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0185","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jep.12619","article-title":"Adherence to guidelines in monitoring amiodarone-induced thyroid dysfunction","volume":"23","author":"Huang","year":"2017","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-17-0018","article-title":"The clinical value of regular thyroid function tests during amiodarone treatment","volume":"177","author":"Benjamens","year":"2017","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ando.2018.05.001","article-title":"Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature","volume":"80","author":"Maqdasy","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0200","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1210\/jc.2014-2745","article-title":"Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis","volume":"100","author":"Lombardi","year":"2015","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"10.1016\/j.ando.2020.04.009_bib0205","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","article-title":"Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo","volume":"124","author":"Ruzieh","year":"2019","journal-title":"The American Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"11","key":"10.1016\/j.ando.2020.04.009_bib0215","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1210\/jc.2019-00990","article-title":"The Effects of Amiodarone on Thyroid Function in Pediatric and Young Adult Patients","volume":"104","author":"Barrett","year":"2019","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CCM.0000000000004078","article-title":"Thyroid Storm in the ICU: A Retrospective Multicenter Study","volume":"48","author":"Bourcier","year":"2020","journal-title":"Critical Care Medicine"},{"issue":"6","key":"10.1016\/j.ando.2020.04.009_bib0225","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.joa.2016.03.008","article-title":"Risk factors for amiodarone-induced thyroid dysfunction in Japan","volume":"32","author":"Kinoshita","year":"2016","journal-title":"Journal of Arrhythmia"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40261-017-0582-4","article-title":"Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction","volume":"38","author":"Yamato","year":"2018","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1016\/j.ando.2020.04.009_bib0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000500355","article-title":"Plasma Beta-Glucuronidase Activity: A Novel Tool to Distinguish Type 1 from Type 2 Amiodarone-Induced Thyrotoxicosis?","volume":"8","author":"Markantes","year":"2019","journal-title":"European Thyroid Journal"},{"issue":"9","key":"10.1016\/j.ando.2020.04.009_bib0240","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/RLU.0000000000002207","article-title":"Amiodarone-Induced Thyrotoxicosis: Differential Diagnosis Using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR)","volume":"43","author":"Censi","year":"2018","journal-title":"Clinical Nuclear Medicine"},{"issue":"6","key":"10.1016\/j.ando.2020.04.009_bib0245","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1089\/thy.2017.0651","article-title":"White Thyroid\u201d on Unenhanced Computed Tomography in Amiodarone-Induced Thyrotoxicosis Type 2","volume":"28","author":"Van den Bruel","year":"2018","journal-title":"Thyroid: official journal of the American Thyroid Association"},{"issue":"4","key":"10.1016\/j.ando.2020.04.009_bib0250","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1210\/jcem-66-4-762","article-title":"Effects of amiodarone therapy on thyroid iodine content as measured by x-ray fluorescence","volume":"66","author":"Fragu","year":"1988","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.ando.2020.04.009_bib0255","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00002018-200629030-00006","article-title":"Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis","volume":"29","author":"Uzan","year":"2006","journal-title":"Drug Safety"},{"issue":"2","key":"10.1016\/j.ando.2020.04.009_bib0260","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1210\/jc.2011-2390","article-title":"Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial","volume":"97","author":"Eskes","year":"2012","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"11","key":"10.1016\/j.ando.2020.04.009_bib0265","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1210\/jc.2011-1678","article-title":"Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study","volume":"96","author":"Bogazzi","year":"2011","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.ando.2020.04.009_bib0270","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/thy.2018.0274","article-title":"Increased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort Study","volume":"29","author":"Gershinsky","year":"2019","journal-title":"Thyroid: official journal of the American Thyroid Association"},{"issue":"5","key":"10.1016\/j.ando.2020.04.009_bib0275","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.tcm.2018.10.003","article-title":"Editorial commentary: Amiodarone-induced thyroid diseases: Additional unintended consequences","volume":"29","author":"Tisdale","year":"2019","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"5","key":"10.1016\/j.ando.2020.04.009_bib0280","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/EJE-19-0515","article-title":"Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis","volume":"181","author":"Campi","year":"2019","journal-title":"European Journal of Endocrinology"},{"issue":"11","key":"10.1016\/j.ando.2020.04.009_bib0285","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/js.2018-00259","article-title":"Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience","volume":"2","author":"Kotwal","year":"2018","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.ando.2020.04.009_bib0290","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fendo.2018.00482","article-title":"Management of Amiodarone-Induced Thyrotoxicosis at a Cardiac Transplantation Centre","volume":"9","author":"Isaacs","year":"2018","journal-title":"Frontiers in Endocrinology"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0295","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz041","article-title":"Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis","volume":"105","author":"Cappellani","year":"2020","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.ando.2020.04.009_bib0300","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12020-018-1661-x","article-title":"Therapeutic plasmapheresis in thyrotoxic patients","volume":"62","author":"Simsir","year":"2018","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.ando.2020.04.009_bib0305","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.amjcard.2016.01.003","article-title":"Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction","volume":"117","author":"Maqdasy","year":"2016","journal-title":"The American Journal of Cardiology"},{"issue":"3","key":"10.1016\/j.ando.2020.04.009_bib0310","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000499104","article-title":"The Use of the Iodine-Rich Drug Amiodarone in the Rapid Preoperative Preparation for Thyroidectomy because of Persistent Hyperthyroidism","volume":"8","author":"Mooij","year":"2019","journal-title":"European Thyroid Journal"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620300664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620300664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:52:49Z","timestamp":1757717569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426620300664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0003426620300664"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.04.009","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amiodarone-induced thyrotoxicosis","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}